‘New paradigm’ moment as mRNA cancer vaccine slashes risk of tumor relapse or death

Pharma giants Merck and Moderna which developed the shot today heralded the results as ‘spectacular’ and a ‘tremendous step forward’. It targets high-risk melanoma.Pharma giants Merck and Moderna which developed the shot today heralded the results as ‘spectacular’ and a ‘tremendous step forward’. It targets high-risk melanoma.Read MoreHealth News | Mail Online